Gyre Therapeutics(GYRE) - 2024 Q2 - Quarterly Results

Exhibit 99.1 Gyre Therapeutics Reports Second Quarter 2024 and Year-To-Date Financial Results and Provides Business Update Received NMPA approval of avatrombopag maleate tablets for the treatment of CLD-associated thrombocytopenia, expanding rare disease product lines Received IND approval from NMPA to evaluate F230 for the treatment of pulmonary arterial hypertension U.S. IND submission for F351 in MASH-associated liver fibrosis expected in late 2024 and data readout from Phase 3 trial in CHB-associated li ...